Moderna to bring mRNA vaccine manufacturing to Australia

14 December 2021
australia_big

US messenger RNA (mRNA) therapeutics and vaccines company Moderna (Nasdaq: MRNA) has announced an agreement in principle with the Australian government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia, including access to Moderna’s mRNA development engine.

The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement.

Moderna expects that up to 100 million vaccine doses could be produced in Australia each year. The facility is intended to also be activated on an urgent basis to support Australia with direct access to rapid pandemic response capabilities. The company is in discussion with other governments about potential collaborations built on a similar model.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology